Fangzhou Inc. Introduces Otsuka's Potent Leukemia Drug Ponatinib Through Its Platform

Fangzhou Inc. Launches Ponatinib for Leukemia Patients

Fangzhou Inc., a prominent player in Internet healthcare solutions, has officially made Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI), Ponatinib (Iclusig®), available on its online platform. This launch provides an expanded array of treatment options for patients diagnosed with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

The Significance of Ponatinib

Approved in China in September 2024, Iclusig® has demonstrated significant efficacy for patients whose diseases are resistant to earlier generations of TKIs, particularly those harboring the T315I mutation of the BCR-ABL1 gene. Clinical findings from the OPTIC trial have highlighted a remarkable survival rate of 88% over four years for certain cohorts of patients treated with Ponatinib. This powerful new option is especially crucial for individuals battling high-risk forms of leukemia.

Dr. Xie Fangmin, the founder and CEO of Fangzhou, expressed the company's dedication to patient-centered healthcare by stating: "As a platform focused on patient-centered healthcare, we are committed to bringing innovative treatments such as Iclusig® to Chinese patients through our digital healthcare ecosystem."

A Deepening Partnership Culture

Fangzhou has established strong collaborations with leading pharmaceutical companies, both domestic and international, to create a robust supply chain capable of addressing diverse health needs. The platform currently offers an impressive catalog of over 210,000 drug SKUs catering to the chronic disease demographic. By employing cutting-edge AI, big data, and cloud computing technologies, Fangzhou not only enhances its health management services but also improves medication safety and patient adherence through its unique AI Personal Health Assistant.